Skip to content
Taxonomy
CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery
CMTA announced today a $423,000 investment to address diagnostic gaps Read More
Simply CMT Podcast Episode 2: Jonah Berger
Welcome to Episode 2 of the Simply CMT Podcast! Join Read More
Encouraging News in CMT Research from CMTA-STAR Alliance Partner Alesta Therapeutics
Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies Read More
CMTA’s New Video Aims to Increase Awareness About CMT
Charcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy, Read More
Nervosave: Shaping the Future of Genetic Therapy for CMT1A
What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, Read More
CMTA-STAR Alliance Partner NMD Pharma Announces FDA Orphan Drug Designation for NMD670
NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that Read More
Simply CMT Podcast
The Simply CMT Podcast is presented by the Charcot-Marie-Tooth Association. Read More
CMTA-STAR Alliance Partner NMD Pharma Publishes Transformative Study on Charcot-Marie-Tooth Disease
CMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication Read More
CMTA Announces New Center of Excellence at Virginia Commonwealth University
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Read More
CMTA Announces New Center of Excellence at Duke University Hospital
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Read More
